Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19063459 | 0.78 | PDE4D (0.42) | PDE4D | |
| SCHEMBL3825639 | 0.75 | CYP11B2 (0.39) | CYP11B2CYP11B1PRKCQ | |
| SCHEMBL15390332 | 0.74 | SRC (0.34) | CYP11B2CYP11B1PRKCQSRC | |
| SCHEMBL1920551 | 0.74 | CYP11B2 (0.40) | CYP11B2CYP11B1 | |
| SCHEMBL27659861 | 0.72 | L3MBTL1 (0.44) | L3MBTL1SRC | |
| SCHEMBL1922370 | 0.72 | PRKCQ (0.39) | CYP11B2CYP11B1PRKCQSRCPDE4D | |
| SCHEMBL2761020 | 0.71 | CYP11B2 (0.45) | CYP11B2CYP11B1 | |
| SCHEMBL23291787 | 0.71 | CSNK1A1 (0.40) | CYP11B2CYP11B1 | |
| SCHEMBL13747989 | 0.71 | CYP11B2 (0.35) | CYP11B2CYP11B1 | |
| SCHEMBL21718417 | 0.71 | CYP11B2 (0.35) | CYP11B2CYP11B1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231663-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |